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Abstract:
Aim: To assess differences in demography, pathology and prognosis with tumor multiplicity in colorectal cancer.
Method: A retrospective single centre study of all patients surgically treated for a colorectal cancer during 1999–2008 (n = 2524). 
Patient characteristics, pathology and follow-up data were retrieved. Survival was assessed by overall and cancer specific survival.
Results: 60 (2.4%) patients had a synchronous cancer (SC), associated with right colon, higher age, more assessed lymph nodes but a 
lower frequency of stage III/IV disease (42% vs. 52%). There was no overall prognostic difference between single or multiple cancer 
patients but females with SC had better survival than corresponding males (P , 0.046).
Conclusion: The incidence of synchronous cancers was 2.4% with the second cancer often located in right colon. The SC patients were 
older than single tumor patients, had a lower frequency of stage III/IV disease and the females with SC had a better survival prognosis 
than corresponding males.
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Introduction
Colorectal cancer is a common cancer form in   Sweden 
and the incidence is slowly increasing.1 There is a 
known risk that a patient can have a second coexist-
ing colorectal cancer.2 Thus, most treatment guide-
lines include some type of colon examination in the 
preoperative work-up to provide the information and 
enable an optimizing the surgical procedure.3 This is 
performed  parallel  to  the  staging  procedure  which 
is aimed at identifying metastatic presence and thus 
for the strategic therapeutic decisions.4 A failure in 
attaining a full bowel exam could mean a risk of not 
attaining radical surgery or even fatally delaying the 
finding and treatment of the second cancer.
The term synchronous cancer (SC) is used when 
there was more than one cancer at the same time. Each 
tumor should also have a separate and definite picture 
of malignancy and they should also be separated by 
macroscopically normal bowel wall. The risk of SC 
in colorectal cancer has been reported at 2%–3%.2,5 
Some known risk factors such as familiar polyposis 
and ulcerative colitis with dysplasia could increase 
the risk.6 Some studies have also found an increased 
frequency of multiplicity in male patients.7,8 The term 
synchronous cancer should be distinguished from both 
metachronous cancer (MC) which occurs later and 
anastomotic recurrences by their location. The risk of 
developing a second and thus metachronous cancer 
has been reported as increased and a colon surveil-
lance should thus be undertaken postoperatively.9,10
The influence by cancer multiplicity on the sur-
vival prognosis in colorectal cancer is less studied. 
Most  reports  on  this  subject  have  not  shown  any 
significant  survival  difference  between  single  and 
multiple  colorectal  cancers.11–13 To  our  knowledge, 
no study has assessed any gender-related differences 
in prognosis with multiple cancers. Still, there are 
several reported findings regarding the difference in 
prognosis between male and female patients with sin-
gle tumor colorectal cancer.14,15 The aim of the study 
was to assess the influence of tumor multiplicity on 
prognosis in colorectal cancer. Secondary aims were 
to identify associated prognostic factors and possible 
gender difference in survival after multiple cancers.
patients and Methods
The study was a retrospective analysis of all patients 
surgically  treated  for  a  colorectal  adenocarcinoma 
during  1999–2008  (n  =  2524)  at  a  single    centre 
  university  hospital.  The  study  was  conducted 
along ethical guidelines and approval by the ethics 
committee.  Patient  characteristics  like  gender 
and  age  were  retrieved  along  with  pathology  data 
(location  of  tumor,  stage,  lymph  nodes,  grading 
and possible tumor multiplicity). Both synchronous 
and metachronous cancers and their incidence were 
identified during the studied period. The 5th edition 
of the TNM classification was used for tumor staging 
purpose during the period.16 For the patients having 
multiple  tumors,  the  one  with  the  most  advanced 
tumor stage was recorded and considered as main 
tumor  for  the  study.  For  multiple  tumors  was  the 
differentiation of main lesion used in the study. The 
patient characteristics were analyzed both by tumor 
multiplicity  and  by  gender.  Survival  was  assessed 
for the cohort with tumor multiplicity. The outcome 
parameters used was overall survival (OS) and cancer 
specific survival (CSS).
Statistical analysis
Statistical  analyses  were  performed  using  JMP 
8.0 software (SAS inc., Cary, NC, USA). Statistical 
tests  performed  included  chi-square,  independent-
samples t-test or ANOVA. All parametric tests show-
ing statistical significance were also controlled with 
non-parametric methods due to the size of the SC 
cohort. Survival was assessed by Kaplan Meier and 
comparisons between groups by log-rank test. A Cox 
proportional hazard analysis was performed for CSS 
both overall and in the SC cohort including prognos-
tic factors significant in univariate survival analysis. 
Findings with two-sided P-values ,0.05 were con-
sidered statistically significant.
Results
Patient characteristics
Of the 2524 assessed patients, 2464 (97.6%) had a sin-
gle tumor and 60 (2.4%) had a second, synchronous, 
tumor. 38 patients (1.5%) developed a metachronous 
tumor during the follow-up. The patients’ characteris-
tics grouped by tumor multiplicity are summarized in 
Table 1. The patients with SC cancers were significantly 
older than the single carcinoma patients (P , 0.026). 
The  postoperative  hospital  stay  was  also  longer 
(P , 0.0047) due to more extensive surgical proce-
dures. There was no difference in differentiation grade, Synchronous Colorectal Cancer
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T-stage or N-stage. With SC it was more likely to have 
a cancer located in the right colon compared to single 
tumor location frequency (P , 0.001). SC was asso-
ciated to more assessed lymph nodes (P , 0.001) as 
the resections were more extensive. There was no dif-
ference in stage distribution (P , 0.07) even though 
advanced disease (stage III and IV) was less frequent 
in the SC group (42% vs. 52%, relative risk 0.67). 
The same pattern was seen for differentiation grade 
but did not reach significance. The stage of the second 
tumor was significantly associated to the main tumor 
(P , 0.001). All statistical significances were valid 
also in non-parametric control tests.
gender and survival
The median follow-up was 64 months. Data on the 
SC patients’ characteristics are presented by gender 
in Table 2. There were more males than females with 
SC  but  not  reaching  statistical  significance.  There 
were  no  significant  gender  related  differences  in 
characteristics or tumor pathology in the SC group. 
Neither was there any difference in tumor   location or 
given treatment. There was no difference in   survival 
regarding multiplicity for the entire cohort (P , 0.2). 
Females with SC had better survival than correspond-
ing males in both OS (P , 0.036) and CSS (P , 0.046), 
shown in Figure 1. Age, T and N stage were signifi-
cant for survival in the multivariate analysis. Gender 
was significant within the SC cohort also in multivari-
ate analysis (P , 0.035). A later development of MC 
did not affect the stage specific survival.
Discussion
The term of multiple colorectal carcinomas   commonly 
include  both  synchronous  (SC)  and  metachronous 
(MC)  tumors. An  important  difference  is  the  time 
frame where SC means coexisting cancers and MC a 
second and thus later developed cancer. The incidence 
in our material of 2.4% and 1.5% respectively concur 
with previous findings.2,5 Despite the low incidence, 
they can constitute a clinical challenge as they need to 
be identified to provide an optimal cancer treatment. 
The consequence is the need of both a preoperative 
colon exam to find a possible SC and the postopera-
tive surveillance for MC or anastomotic recurrences. 
The  risk  of  having  a  second  tumor  located  in  the 
right colon was high in this material (P , 0.001). 
Thus is a full colonic examination, by radiology or 
endonoscopy, necessary to negate the presence of a 
second cancer.
Table 1. Patients characteristics by tumor multiplicity in a patient cohort operated for colorectal adenocarcinoma (n = 2524).
characteristics single carcinoma  
group (n = 2464)
Double carcinoma  
group (n = 60)
statistics
Age (mean ± sd) 69.2 ± 0.3 72.9 ± 1.6 P , 0.026*
gender (M/F) 1220/1244 35/25 P , 0.17
Colon/rectum (n) 1531/933 37/23 P , 0.91
Stage I/II/III/IV 275/833/869/409 12/23/17/8 P , 0.070
grade: high/medium/ 
low/undiff
119/1624/484/153 3/43/10/4 P , 0.91
Assessed nodes  
(mean ± sd)
15.9 ± 0.2 26.8 ± 1.3 P , 0.001*
Positive nodes in stage III  
(mean ± sd)
3.1 ± 0.1 3.2 ± 0.5 P , 0.98
Length of  
stay (mean ± sd)
11.1 ± 0.2 14.5 ± 1.2 P , 0.0047*
note: Statistical significance (P , 0.05) is marked with*.
Table  2.  Characteristics  of  patients  with  synchronous 
  colorectal cancers (n = 60) shown by gender.
characteristics Male  
(n = 35)
Female  
(n = 25)
statistics
Age (mean ± sd) 71 ± 2.3 75 ± 2.6 P , 0.19
Colon/rectum (n) 20/15 17/8 P , 0.53
Stage: I/II/III/IV 2/11/15/7 2/10/11/2 P , 0.44
grade: high/ 
medium/low/undiff
1/25/7/2 2/18/3/2 P , 0.69
Assessed nodes  
(mean ± sd)
30 ± 3.7 22 ± 4.3 P , 0.12
Positive nodes  
in stage III  
(mean ± sd)
4.4 ± 1.6 1.7 ± 1.3 P , 0.13Derwinger and gustavsson
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There were more males in the SC group which is 
a characteristic that concur with previous findings7,8 
although  the  difference  did  not  reach  statistical 
  significance. The mechanisms underlying gender dif-
ferences in tumor multiplicity are presently unknown. 
Hormone effects have been suggested as testoster-
one  can  affect  the  immune  function  negatively  in 
men and female sex steroids could have a protective 
immune role in human colon tumors. Estrogen and 
progesterone receptors in colorectal cancer messen-
ger  RNAs  coding  has  also  been  found.15 Another 
characteristic of the SC group is the higher age of the 
group and foremost of the females. The significantly 
higher age in this SC material do also concur with 
other  publications.2,17,18  As  females  normally  have 
longer life-spans and thus at higher age constitute a 
higher proportion of the cancer patients it could have 
been  expected  to  find  a  higher  female  representa-
tion in the SC cohort. This aspect could strengthen 
the  hypothesis  of  a  higher  incidence  for  males  as 
  discussed above.
There  was  no  significant  difference  in  survival 
between the single carcinomas and the SC cohort. 
Neither was there any difference any overall cancer 
stage or stage specific survival. The SC patients were 
more likely to be operated with more extensive resec-
tions and thus yielding higher lymph node assessment 
counts. Having more than one cancer should hypo-
thetically increase the risk of at least one providing 
node metastasis and thus higher rates of stage III. 
However, this was not observed and the frequency of 
advanced disease (stage III and IV) was even less in 
the SC group (42% vs. 52%). The absence of statisti-
cal difference between single and multiple carcinomas 
regarding mortality and survival has been previously 
described.11,12,19,20 The finding of a better survival, both 
OS and CSS, for females in the SC cohort is inter-
esting. There was no pathology or staging (Table 2) 
differences between the genders which could explain 
the result. One possibility, often difficult to negate, 
could be a bias due to the longer life expectancy of a 
female. However, the finding also on CSS could sug-
gest that there could be a survival difference.
Another  possible  explanation  could  be  in  an 
  alternate pathway of carcinogenesis. Jass et al have 
suggested that colorectal cancer could be a   summary 
of  several  different  entities,  each  with  its’  own 
characteristic.21,22 The theory involves diverse bio-
  molecular  differences  including  in  Microsatellite 
instability (MSI) which has been found to be sig-
nificantly  higher  in  multiple  carcinomas.23–25 
  Interestingly, one group described by Jass et al devel-
ops through serrated polyps rather than adenomas 
and can be associated to females and high MSI.22 
Other  associated  findings  such  as  alterations  in 
gene methylation have been reported by Wettergren 
and Odin, suggesting that there are changes in the 
bowel mucosa also at longer distances away from 
the tumor.26,27 The findings could support a theory of 
extensive mucosal changes leading to development 
of multiple carcinomas. Further studies on the bio-
molecular properties of the tumors and mucosa could 
be of great interest. An alternate pathway of cancer 
development could then hypothetically results in dif-
ferent cancer characteristics and even prognosis. The 
low incidence of metachronous cancers could sug-
gest that the bio-molecular changes in the mucosa 
discussed above are reversible.
0.0
0 500 1000 1500 2000 2500 3000 3500
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0.0
0 500 1000 1500 2000 2500 3000 3500
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Male (n = 35) Male (n = 35)
Female (n = 35) Female (n = 25)
P < 0.046 P < 0.036
Overall survival Cancer specific survival
Figure 1. Gender-related difference in overall and cancer specific survival in a cohort (n = 60) of patients with synchronous colorectal cancer.Synchronous Colorectal Cancer
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The study indicates that there could be a gender 
associated difference in the survival prognosis in syn-
chronous colorectal cancer. As SC also is more com-
mon at higher age a possible underlying explanation 
could be an alternate pathway for tumor development. 
The  patients  in  the  study  represent  a  consecutive, 
unselected material of which we have valid clinical 
data. In being a single centre study, they have all 
been assessed and treated along the same guidelines. 
Whilst it is, to our knowledge, one of the larger single-
centre materials on the subject there is a weakness in 
the rather small number of SC patients due to a low 
incidence. We did not further analyze survival and 
prognosis for the MC patients, which mainly is stage 
dependent for the second cancer as a MC prerequisite 
is a good survival from the first. MC and SC are, in 
our opinion, two separate entities and should thus be 
handled in analysis and evaluation.
conclusion
The incidence of synchronous cancers was 2.4% with 
the second cancer often located in right colon. The 
SC patients were older than single tumor patients, 
had a lower frequency of stage III/IV disease and the 
females with SC had a better survival prognosis than 
corresponding males.
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